B.1.351 – Page 2 – Communicable Diseases Research

Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey

Article

Published on 2022-10-262022-11-15
Journal: mBio [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, 치료기술,

[키워드] acute respiratory syndrome antibody antibody resistance attack rate B.1.351 B.1.526 Care caused characteristic Clinical use collected Community Complete coronavirus COVID-19 Critical E484K mutation Evidence Examining exhibit exhibited hcp Health highlight individual infected individuals Infection Inpatient Lineage loss of activity monoclonal antibody Mutation N-terminal domain neutralization capacity Neutralizing antibody response neutralizing capacity New nosocomial NTD outbreak P.1 Patient plasma positive professional professionals proportion pseudovirus psychiatric facility Receptor binding domain reported reverse transcription robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant sera Spike protein Symptom symptomatic COVID-19 disease tested the SARS-CoV-2 the United State treat vaccinated individual vaccinated individuals vaccination Vaccine variant variants of concern VOCs wild type
[DOI] 10.1128/mbio.02141-22 PMC 바로가기

Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021

Article

Published on 2022-10-032022-11-16
Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종,

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge

Article

Published on 2022-10-012022-11-15
Journal: Translational research : the journal of laboratory [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술,

[키워드] amino acid change antibody B.1.1.529 B.1.1.7 B.1.1.7 lineage B.1.351 B.1.427 B.1.429 B.1.617.1 B.1.617.2 Beta Combination D614G mutation Delta disease severity domain E484K evaluated expressing Gamma greater highlight human-to-human transmission induce L452R Lineage lineages mice moderate mouse-adapted SARS-CoV-2 mRNA vaccine Multiple multiple mutations Mutation mutations N439K N501Y neutralization neutralized Neutralizing activity neutralizing antibody observation omicron other variant P.1 P681R pandemic PROTECT Protein pseudotyped pseudovirus reduced SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants serum antibody T478K the S protein Transmissibility vaccination Vaccine variant variants virulent
[DOI] 10.1016/j.trsl.2022.04.007 PMC 바로가기

Factors That Affect the COVID-19 Pandemic in Summer 2022 Compared to Summer 2021

Article

Published on 2022-10-012022-11-16
Journal: International Journal of Environmental Research an [Category] COVID19(2023년), SARS, 변종,

An isothermal lab-on-phone test for easy molecular diagnosis of SARS-CoV-2 near patients and in less than 1 hour

Article

Published on 2022-10-012022-11-15
Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술,

Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19

Research article

Published on 2022-10-012022-10-05
Journal: Antiviral Research [Category] COVID19(2023년), SARS, 변종, 치료법, 치료제,

[키워드] acute respiratory syndrome Antiviral antiviral activity Antiviral treatment B.1.351 B.1.617.2 Beta Brequinar cellular Combination coronavirus coronavirus disease COVID-19 de novo deaths Delta DHODH Dihydroorotate dehydrogenase (DHODH) Dipyridamole drug treatments effective enzyme evade Evolution of SARS-CoV-2 exhibit global pandemic Host host cell in vitro Infection infections inhibitor maintain medical need monoclonal antibody nucleotide pathway rationale Replication required resulting RNA virus SARS-CoV-2 SARS-COV-2 infection selective shown Support synergistic therapy treat Treatment Vaccine variants viral replication
[DOI] 10.1016/j.antiviral.2022.105403 [Article Type] Research article

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses

Article

Published on 2022-09-202022-11-15
Journal: Frontiers in Immunology [Category] SARS, 변종, 진단,

Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern

Article

Published on 2022-09-172022-11-15
Journal: Journal of Travel Medicine [Category] SARS, 변종, 진단, 치료기술,

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants

Article

Published on 2022-09-142022-11-16
Journal: PLoS ONE [Category] SARS, 변종,

A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection

Article

Published on 2022-09-142022-11-15
Journal: Journal of Virology [Category] SARS, 변종, 진단,

[키워드] Affect antibody production B.1.1.529 B.1.1.7 lineage B.1.351 B.1.427 B.1.429 B.1.617.2 Beta coronavirus COVID-19 COVID-19 vaccine Delta delta variant demonstrated develop disease severity domain effective effective vaccine Effectiveness Efficacy elicited enhanced enhanced protection epitope Epsilon Gamma global public health highlight human ACE2 immunized immunized mice immunodominant IMPROVE Improved improved neutralizing activity induce Lineage mice mutant mutated Mutation Neutralizing Neutralizing activity neutralizing antibody Neutralizing antibody titer Numerous omicron Omicron and other variants Other P.1 pandemic Prevent probe protection Protective Protein pseudotyped pseudovirus RBD RBD protein SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants shown significantly Strains subunit Subunit vaccine the receptor-binding domain threat Transmissibility Vaccine variant variants weight loss
[DOI] 10.1128/jvi.00118-22 PMC 바로가기